Kymera Therapeutics

Kymera Therapeutics KYMR Stock

$125.85   -1.348280%
Add to favorites
Market Cap
$10.74B
LOW - HIGH [24H]
$123.67 - $128.94
VOLUME [24H]
$912.37K
P/E Ratio
0
Earnings per share
-$3.64
ISIN
US5015751044
Price   Prediction

Kymera Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Kymera Therapeutics (KYMR) stock price today is 125.85 USD on Tech Market Middle (-1.35% on the day). Updated .

Kymera Therapeutics KYMR Financial and Trading Overview

Kymera Therapeutics stock price 125.85 USD
Previous Close 127.57 USD
Open 127.44 USD
Bid 75.27 USD x 200
Ask 133.99 USD x 200
Day's Range 123.67 - 128.94 USD
52 Week Range 62.91 - 142.92 USD
Volume 912.37K USD
Avg. Volume 834.11K USD
Market Cap 10.74B USD
Beta (5Y Monthly) 2.029
PE Ratio (TTM) N/A
EPS (TTM) -3.64 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 145.22 USD

KYMR Valuation Measures

Enterprise Value 9.85B USD
Trailing P/E N/A
Forward P/E -24.589106
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 105.09112
Price/Book (mrq) 6.650988
Enterprise Value/Revenue 96.341
Enterprise Value/EBITDA -24.723

Trading Information

Kymera Therapeutics Stock Price History

Beta (5Y Monthly) 2.029
52-Week Change 99.01%
S&P500 52-Week Change 13.32%
52 Week High 142.92 USD
52 Week Low 62.91 USD
50-Day Moving Average 117.13 USD
200-Day Moving Average 99.45 USD

KYMR Share Statistics

Avg. Volume (3 month) 834.11K USD
Avg. Daily Volume (10-Days) 1.13M USD
Shares Outstanding 85.37M
Float 68.26M
Short Ratio 9.52
% Held by Insiders 3.22%
% Held by Institutions 116.67%
Shares Short 8.4M
Short % of Float 12.57%
Short % of Shares Outstanding 9.84%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -396.038%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -17.63%
Return on Equity (ttm) -27.29%

Income Statement

Revenue (ttm) 102.24M USD
Revenue Per Share (ttm) 1.06 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -327748000 USD
EBITDA -398383008 USD
Net Income Avi to Common (ttm) -349424992 USD
Diluted EPS (ttm) -3.64
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 971.21M USD
Total Cash Per Share (mrq) 11.38 USD
Total Debt (mrq) 76.6M USD
Total Debt/Equity (mrq) 4.74 USD
Current Ratio (mrq) 11.13
Book Value Per Share (mrq) 18.922

Cash Flow Statement

Operating Cash Flow (ttm) -287564992 USD
Levered Free Cash Flow (ttm) -164682000 USD

Profile of Kymera Therapeutics

Country United States
State MA
City Watertown
Address 500 North Beacon Street
ZIP 02472
Phone 857 285 5300
Website https://www.kymeratx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 285

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Q&A For Kymera Therapeutics Stock

What is a current KYMR stock price?

Kymera Therapeutics KYMR stock price today per share is 125.85 USD.

How to purchase Kymera Therapeutics stock?

You can buy KYMR shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Kymera Therapeutics?

The stock symbol or ticker of Kymera Therapeutics is KYMR.

Which industry does the Kymera Therapeutics company belong to?

The Kymera Therapeutics industry is Biotechnology.

How many shares does Kymera Therapeutics have in circulation?

The max supply of Kymera Therapeutics shares is 85.37M.

What is Kymera Therapeutics Price to Earnings Ratio (PE Ratio)?

Kymera Therapeutics PE Ratio is now.

What was Kymera Therapeutics earnings per share over the trailing 12 months (TTM)?

Kymera Therapeutics EPS is -3.64 USD over the trailing 12 months.

Which sector does the Kymera Therapeutics company belong to?

The Kymera Therapeutics sector is Healthcare.

Kymera Therapeutics KYMR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24509.76 USD —
-2.49
8.22B USD — 24460.28 USD — 24882.04 USD — — 8.22B USD —
us US Tech US 700 Small Cap Index NQUS700SC US 2969.43 USD —
-1.69
— — 2963.14 USD — 3004.79 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3666.28 USD —
-2.18
— — 3658.64 USD — 3712.3 USD — — — —
us US Tech Biotechnology NBI US 7068.28 USD —
-1.98
— — 7052.81 USD — 7247.79 USD — — — —
us US Tech Health Care IXHC US 1342.75 USD —
-1.87
— — 1340.49 USD — 1374 USD — — — —
us US Tech Global Market Composite NQGM US 1868.76 USD —
-3.56
— — 1866.47 USD — 1913 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.2T
Total marketcap
$77.29B
Total volume
BTC 59.24%   •   ETH 10.10%
Dominance
Select currency